WA pharmaceutical marketing company Helicon Group has come up with a very smart plan to penetrate the world’s most enticing market – China – by targeting its newly emerging middle class.

Winning the 2008 NSW BioFirst Commercialisation award has come at exactly the right time for Special Phage Holdings, which has treated a patient in the clinic and is currently looking at a second round of private fundraising to develop its portfolio of bacteriophages

Arana humanises VEGF-D antibody

Xceed and Metabolic trade PolyNovo Biomaterials

Alchemia registers loss, expects to be in profit in 2010

NuSep to purchase NxGen for $25 million

The antisense concept has been around for 30 years and now therapies are on the market and in the clinic, including a recently reported Phase IIa trial by Melbourne company Antisense Therapeutics.

Unlisted Queensland biotech Xenome has reported good results in a Phase II trial of its candidate for chronic cancer pain relief and raised a good amount of cash to further its clinical development.

Arana files IND application for rheumatoid arthritis candidate

Neuren, Norwood Abbey, NuSep, Anadis, Incitive, Ambri

Western Australian company Orthocell is pioneering biological therapies to repair and regenerate damaged tendons and ligaments.